Study shows alarming trends in mortality from alcoholic cirrhosis in the U.S.

Alcoholic cirrhosis is an advanced form of alcohol-related liver disease. In the United States between 2010 and 2016, alcohol-related liver disease was the primary cause of nearly 1 in 3 liver transplants, surpassing hepatitis C.

Researchers from Florida Atlantic University's Schmidt College of Medicine conducted an original research study utilizing the U.S. Centers for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (WONDER) to compare trends in mortality from alcoholic cirrhosis in the U.S. in 1999 with those 20 years later in 2019. They calculated mortality rates and mortality rate ratios (MRRs) per 100,000 from alcoholic cirrhosis in 10-year age groups from ages 25 to 85 and older as measures of effect and 95 percent confidence intervals to test for significance.

Results of the study, published online ahead of print in The American Journal of Medicine, showed that in 1999 there were 6,007 deaths from alcoholic cirrhosis among 180,408,769 Americans ages 25 to 85 and older yielding a mortality rate of 3.3 per 100,000. In 2019, there were 23,780 deaths from alcoholic cirrhosis among 224,981,167 Americans ages 25 to 85 and older, yielding a mortality rate of 10.6 per 100,000.

"It is very sobering that in the United States between 1999 and 2019, we saw a greater than three-fold increase in deaths from alcoholic cirrhosis," said Lawrence Fiedler, M.D., co-author, a board-certified practicing gastroenterologist and an affiliate associate professor in FAU Schmidt College of Medicine. "Damage from chronic and excessive alcohol intake results in fatty liver disease and alcoholic hepatitis. Over time, this results in scarring and cirrhosis, the final and irreversible phase of alcoholic liver disease."

In the U.S. between 1999 and 2019 there also were statistically significant increases in mortality from alcoholic cirrhosis in each 10-year age group from 25 to 85 and older. It also is notable that the largest increase was seven-fold in the age group 24 to 35 years and that the steepest increase was among those ages 65 to 74.

While more research in necessary, these alarming trends in mortality from alcoholic cirrhosis pose immediate clinical and public health challenges to curb the epidemics of heavy alcohol consumption as well as overweight and obesity and lack of physical activity in the U.S., all of which may be contributory."

Charles H. Hennekens, M.D., Dr.PH, corresponding author, first Sir Richard Doll Professor of Medicine and senior academic adviser, FAU Schmidt College of Medicine

The researchers note that primary care providers may want to counsel all their patients that individuals who consume large amounts of alcohol have the highest mortality rates from both cirrhosis and cardiovascular disease. While the data indicate that those who select one to two drinks daily have lower risks of cardiovascular disease than nondrinkers, it is also true that the difference between drinking smaller and larger amounts of alcohol means the difference between preventing and causing premature death.

"Specifically, rates of myocardial infarction and stroke as well as hypertension, hemorrhagic stroke and breast cancer all begin to rise above one drink daily, especially in women," said Hennekens. "In addition, the impacts of increased alcohol consumption at earlier ages as well as overweight and obesity and lack of physical activity all may contribute, alone and in combination, to the observed increases in mortality from alcoholic cirrhosis."

Source:
Journal reference:

Termeie, O., et al. (2022) Alarming Trends: Mortality from Alcoholic Cirrhosis in the United States. The American Journal of Medicine. doi.org/10.1016/j.amjmed.2022.05.015.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine